Still’s Disease Treatment Market, by Treatment (Pain Management, Corticosteroids, Tocilizumab, Canakinumab, Anakinra, and Others), by Route of Administration (Injectable and Oral), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Onlin

Still’s Disease Treatment Market, by Treatment (Pain Management, Corticosteroids, Tocilizumab, Canakinumab, Anakinra, and Others), by Route of Administration (Injectable and Oral), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Still’s disease, also known as adult-onset Still's disease (AOSD), is a rare type of inflammatory disorder associated with joint pain, rash, and fevers. This devastating condition may lead to long-term chronic arthritis and can result in permanent disabilities. Still's disease is related to the rash that does not itch and high spiking fever. This disorder can destroy affected joints, mainly the wrists. The treatment of Still’s disease involves medications that help inflammation.
Market Dynamics
The increase in funding for research and development to develop novel therapies and treatment coupled with increasing prevalence of Still’s disease are the major factors boosting growth of the global still’s disease treatment market. For instance, according to WebMD, Still's disease is more prevalent in women and affects less than 1 in 100,000 people across the globe develop Still's or adult-onset still’s each year.
Moreover, the emergence of drugs for the treatment of complications related to Still's disease is another factor propelling the market growth. For instance, in July 2020, the U.S. Food and Drug Administration (FDA) expanded the use of Canakinumab (Ilaris) for all patients with active Still's disease older than 2 years. Therefore, the drug can now be used for the adult-onset Still's disease (AOSD), which was previously approved for only juvenile-onset Still's disease.
However, the lack of healthcare finance in some low- and middle-income countries and patent expiration of drugs are some of the major factors restricting growth of the global still’s disease treatment market.
Key features of the study:
This report provides in-depth analysis of the global still’s disease treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global Still’s disease treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include F. Hoffmann-La Roche Ltd, Swedish Orphan Biovitrum AB, Novartis AG, Jubilant Life Sciences Ltd, AB2 Bio Ltd., Hikma Pharmaceuticals PLC, Dr Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., Zydus Cadila, Horizon Therapeutics plc, Amneal Pharmaceuticals LLC, Fresenius Kabi AG., and Vintage Labs
Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global still’s disease treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Still’s disease treatment market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Still’s Disease Treatment Market, By Treatment:
Pain Management
Corticosteroids Therapy
Tocilizumab
Canakinumab
Anakinra
Others
Global Still’s Disease Treatment Market, By Route of Administration:
Injectable
Oral
Global Still’s Disease Treatment Market, By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Global Still’s Disease Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Treatment:
Pain Management
Corticosteroids Therapy
Tocilizumab
Canakinumab
Anakinra
Others
By Route of Administration:
Injectable
Oral
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Treatment:
Pain Management
Corticosteroids Therapy
Tocilizumab
Canakinumab
Anakinra
Others
By Route of Administration:
Injectable
Oral
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Treatment:
Pain Management
Corticosteroids Therapy
Tocilizumab
Canakinumab
Anakinra
Others
By Route of Administration:
Injectable
Oral
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Treatment:
Pain Management
Corticosteroids Therapy
Tocilizumab
Canakinumab
Anakinra
Others
By Route of Administration:
Injectable
Oral
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Treatment:
Pain Management
Corticosteroids Therapy
Tocilizumab
Canakinumab
Anakinra
Others
By Route of Administration:
Injectable
Oral
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Treatment:
Pain Management
Corticosteroids Therapy
Tocilizumab
Canakinumab
Anakinra
Others
By Route of Administration:
Injectable
Oral
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Company Profiles
F. Hoffmann-La Roche Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Swedish Orphan Biovitrum AB
Novartis AG
Jubilant Life Sciences Ltd
AB2 Bio Ltd.
Hikma Pharmaceuticals PLC
Dr Reddy's Laboratories Ltd.
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Mylan N.V.
Zydus Cadila
Horizon Therapeutics plc
Amneal Pharmaceuticals LLC
Fresenius Kabi AG
Vintage Labs
“*” marked represents similar segmentation in other categories in the respective section.